Ketamine Therapy for Bipolar Depression

Ketamine has produced rapid antidepressant effects in small studies of people in a bipolar depressive episode, including people whose depression hadn't improved on standard treatment. The evidence base is far smaller than it is for unipolar depression, and it comes with two conditions attached that get lost in most summaries.

The first is that nearly all of this research gave ketamine on top of an existing mood stabilizer, not instead of one. The second is that researchers watch closely for treatment-emergent mania or hypomania, because a drug that lifts mood quickly raises an obvious question in bipolar disorder.

Ketamine for bipolar depression is off-label in every form. Spravato is not FDA approved for bipolar depression. Current treatment guidelines place ketamine well down the list rather than near the front.

Bipolar Depression Is Not the Same as Major Depression

The depressive episodes can look similar from the inside. The illness around them is different, and that difference changes almost everything about treatment.

Bipolar disorder involves a history or risk of mania or hypomania. That shapes which medications are appropriate, makes antidepressant decisions more complicated, and adds mood monitoring that unipolar treatment doesn't require. It also means research done in major depressive disorder can't simply be assumed to transfer.

So when a study reports that ketamine helped depression, the first question is which depression. Our guide on ketamine therapy for depression covers the unipolar evidence, which is much larger and shouldn't be read as covering this.

What Does the Evidence for Ketamine in Bipolar Depression Show?

A consistent short-term signal, from a very small base.

A 2023 updated systematic review pooled 8 studies with 235 participants: three randomized trials, four open-label or single-arm studies, and one real-world observational study. Across them, 48 percent of ketamine recipients responded, compared with 5 percent of those on placebo. Response rates varied substantially across the included studies.

A separate 2023 systematic review and meta-analysis is where the limits become obvious. It included 11 studies, 7 in the meta-analysis, and of those only two were randomized trials with 33 participants between them. The non-randomized studies showed 53 percent response and 38 percent remission.

Those pooled percentages describe heterogeneous groups of study participants. They aren't a success rate you can apply to yourself, and two randomized trials totaling 33 people is not a settled evidence base.

Why the Mood Stabilizer Matters in These Studies

This is the most important thing to understand about the bipolar ketamine literature.

In the 2023 review, every participant who received IV ketamine got it at 0.5 to 0.75 mg/kg as an adjunctive treatment to a mood-stabilizing agent. Both landmark randomized trials enrolled patients maintained on therapeutic levels of lithium or valproate, and gave ketamine on top of that.

So what the research supports is ketamine added to an established bipolar regimen. It is not evidence that ketamine works instead of a mood stabilizer, because no bipolar trial tested that. Anyone describing ketamine as a standalone bipolar treatment is going beyond the studies.

None of this is a reason to change what you take. Decisions about lithium, valproate, lamotrigine, or anything else belong with your prescriber, and our guide on ketamine and other medications covers how those conversations usually go.

How Quickly Can Ketamine Affect Bipolar Depression?

Fast, in the trials that measured it closely.

In the randomized replication trial, depressive symptoms improved significantly within 40 minutes of the infusion compared with placebo, and the improvement remained significant through day three. That speed is a large part of why ketamine drew interest in severe treatment-resistant bipolar depression at all.

Two caveats. These were group averages in tiny samples, so individual experience varied widely. And onset tells you nothing about durability, which is a separate question with a less satisfying answer.

How Long Does the Benefit Last?

Most of the bipolar research studied a single infusion with short follow-up.

In the randomized trials, the separation from placebo held for around three days. The 2023 review noted limited follow-up data beyond two weeks across the entire literature. Benefit fading after a single dose isn't treatment failure; it's what a single dose of a short-acting intervention does.

There's no bipolar-specific maintenance protocol established by evidence, which is a real gap rather than a detail. Our guide on the long-term effects of ketamine therapy covers what the longer datasets show, almost all of it in unipolar depression.

Does Repeated Ketamine Work for Bipolar Depression?

The serial-infusion evidence is thinner than the single-dose evidence, and mostly uncontrolled.

Studies using repeated infusions have reported response and remission rates in the ranges above, but they are largely open-label, without a comparison group, and small. The 2023 meta-analysis found only non-randomized studies contributing to the repeated-treatment picture.

Where those studies used a particular schedule, treat it as a research protocol rather than a recommendation. No trial has established an optimal number of infusions, interval, or duration for bipolar depression, and borrowing a unipolar schedule doesn't fill that gap.

Can Ketamine Trigger Mania or Hypomania?

It can happen. The published studies don't show that it happens often.

Manic and hypomanic symptoms were uncommon across the published studies, but the exact rate is uncertain. One 2023 systematic review reported several events spread across ketamine, esketamine, and placebo groups, and its own summary counts were not fully consistent.

A separate 2023 review gives a cleaner number. Manic or hypomanic symptoms were reported in 5 of 208 participants receiving IV ketamine, about 2.4 percent, with a confidence interval running from roughly 0.3 to 4.5 percent.

That is an observed rate in small, heterogeneous studies, not your predicted risk. Follow-up was short, definitions of a switch varied, nearly everyone continued a mood stabilizer, and people at highest risk were often excluded.

Signs worth reporting promptly include a sharply reduced need for sleep, a rapid jump in energy, unusually elevated or irritable mood, racing thoughts, or impulsive behavior. Contact your treating clinician if those appear.

Why the Switch-to-Mania Question Is Hard to Answer

Because bipolar disorder produces mood switches on its own, and the studies aren't built to separate the two.

Samples are tiny. Follow-up is measured in days or weeks. Most participants continued mood stabilizers, so the observed rate reflects ketamine plus protection rather than ketamine alone. Trials frequently excluded people with recent mania or unstable presentations, which is exactly the group whose risk you'd most want to know. Bipolar I and bipolar II may not behave the same way, and the studies rarely have the numbers to check.

Case reports of mania after ketamine exist, and a case report describes what happened to one person without establishing what caused it. That's why researchers write "treatment-emergent" rather than "ketamine-induced." Saying ketamine doesn't cause mania overstates the reassurance; saying it frequently does overstates the alarm.

Bipolar I vs. Bipolar II Depression

The honest answer is that the studies can't settle this.

The randomized trials enrolled people with bipolar I or bipolar II and analyzed them together. Sample sizes of 15 and 18 leave no room for meaningful subtype comparison. Nobody has shown ketamine works better for one than the other.

Treatment guidance does distinguish them slightly. Adjunctive IV ketamine appears as a third-line option for acute bipolar I depression, while for bipolar II the 2023 guideline update lists adjunctive ketamine given intravenously or sublingually among third-line options.

What If Someone Has Mixed Features?

Mixed features means depressive symptoms occurring alongside meaningful manic or hypomanic symptoms at the same time.

This is where the evidence essentially stops. Bipolar ketamine trials generally excluded people with current mania, hypomania, or unstable presentations, so the population that has been studied is people in a relatively clean depressive episode.

That makes extrapolation to someone with substantial current manic symptoms unsupported. It isn't a statement that treatment is impossible in that situation. It's that the research doesn't speak to it, and a clinician weighing it is working from judgment rather than trial data.

What Does Current Bipolar Treatment Guidance Say About Ketamine?

The CANMAT and ISBD guidelines, in their 2023 evidence update, place adjunctive IV ketamine as a third-line option for acute bipolar I depression. For acute bipolar II depression, they list ketamine given intravenously or sublingually as a third-line adjunctive option.

Third-line means generally considered after better-established options have been tried, haven't worked well enough, or aren't suitable. It doesn't mean ineffective or unsafe. It reflects how much evidence exists relative to the alternatives.

For context, first-line options for acute bipolar depression in those guidelines include quetiapine, lurasidone, lithium, lamotrigine, and cariprazine. Those rest on much larger trials.

What About Spravato for Bipolar Depression?

Spravato is not FDA approved for bipolar depression, and this is a place where careful reading matters.

Its US psychiatric indications are treatment-resistant depression in adults, and depressive symptoms in adults with major depressive disorder who have acute suicidal ideation or behavior. "Treatment-resistant depression" there refers to major depressive disorder. It does not silently include treatment-resistant bipolar depression, and the pivotal trial program didn't study bipolar patients.

The bipolar-specific esketamine evidence is small and non-randomized. The most substantial piece is a real-world study of 35 people with treatment-resistant bipolar depression given intranasal esketamine. Response and remission were 25.7 and 17.1 percent at one month, rising to 68.6 and 48.6 percent at two months. No manic or hypomanic switches were observed, and outcomes were broadly comparable to unipolar patients.

That's worth knowing and it isn't a randomized trial. Our guide on Spravato treatment covers its approved use, and IV ketamine vs. Spravato explains why findings for one don't automatically transfer to the other.

What About Oral or Sublingual Ketamine?

The 2023 guideline update lists adjunctive sublingual ketamine among third-line options for bipolar II depression, which is the strongest formal endorsement any oral route has here.

Newer work exists but is harder to apply. A 2026 randomized trial and meta-analysis examined oral ketamine in people with major depressive disorder or bipolar disorder. The trial gave 1 mg/kg orally against midazolam six times over two weeks, and the meta-analysis covered 592 patients. The published summary reports combined results across both diagnoses.

I could not identify separately reported bipolar outcomes in the accessible material, so that pooled result shouldn't be treated as bipolar-specific evidence. A study that enrolls both populations and reports them together tells you about depression broadly, not about bipolar depression particularly.

Does Ketamine Reduce Suicidal Thoughts in Bipolar Depression?

There is a bipolar-specific signal, and it's inconsistent.

The randomized replication trial found suicidal ideation improved significantly within 40 minutes alongside depressive symptoms. The 2023 review found large reductions in suicidal symptoms across trials, but the statistical significance varied. One open-label trial showed significance at four hours. One randomized trial found no significant difference between ketamine and midazolam, and another found changes only among people whose depression responded.

None of that establishes that ketamine prevents suicide. For Spravato specifically, the label states plainly that its effectiveness in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated. Its acute-suicidality indication also concerns major depressive disorder, not bipolar depression.

Is Ketamine a First-Line Treatment for Bipolar Depression?

No, and no current guideline positions it that way.

Established bipolar treatments have far larger evidence bases behind them, built from bigger trials with longer follow-up. Ketamine sits later in the sequence for a straightforward reason: two small randomized trials cannot compete with that.

It becomes worth discussing when established treatments haven't produced enough improvement, weren't tolerated, or when the speed of response matters clinically. That's a conversation with a clinician who knows your history, not a conclusion to draw from an article.

Who Might Be Considered for Ketamine?

Looking at who was actually studied is more useful than a candidacy checklist.

Participants were adults in a current bipolar depressive episode, generally with depression that hadn't responded to standard treatment, continuing mood-stabilizing medication, medically stable, and without current uncontrolled mania.

Real candidacy is individual, and a bipolar diagnosis does not automatically exclude anyone from ketamine treatment. Our guides on who is a good candidate and who shouldn't get ketamine therapy cover how those judgments get made.

What Should a Provider Screen for Before Treatment?

Bipolar disorder raises the bar on screening.

A careful evaluation covers whether the bipolar diagnosis is correct in the first place, which subtype, and whether manic or hypomanic symptoms are present now. It also covers mixed features, recent mood cycling, and any history of treatment-emergent mania on other medications. It also covers current mood stabilizers and other psychiatric medications, substance use, psychotic symptoms where relevant, and medical fitness for the treatment.

Our guides on ketamine and other medications and how to choose a ketamine clinic go into both sides of that.

What Are the Biggest Gaps in the Research?

The specific missing pieces are easy to name:

Randomized evidence totaling 33 participants across two trials
Almost no follow-up beyond two weeks
No established maintenance protocol for bipolar depression
Switch risk estimated from small samples where nearly everyone was on a mood stabilizer
No adequate comparison between bipolar I and bipolar II
Essentially no evidence in people with current mixed features
Esketamine evidence limited to small non-randomized studies
No test of whether ketamine works without a concurrent mood stabilizer
Oral and sublingual evidence that rarely separates bipolar from unipolar results
Inconsistent suicidal-ideation findings
No way to predict who responds
No large head-to-head trials against established bipolar treatments

Questions to Ask a Ketamine Provider About Bipolar Depression

How much experience do you have treating bipolar depression specifically?
Are you treating bipolar depression, or unipolar treatment-resistant depression?
How do you screen for current mania, hypomania, or mixed features?
How does my mood stabilizer fit into the plan?
What evidence supports the route you're recommending?
How will you monitor for a mood switch, and what would you do if one started?
How will we decide whether this is helping?
Is what you're recommending FDA approved for bipolar depression?

Finding a Provider for Bipolar Depression

The right provider here is someone who treats bipolar disorder, not someone who treats depression and is willing to make an exception.

That means understanding mood stabilizers, watching for switches as a matter of routine, and being straightforward that this use is off-label. It also means knowing the difference between ketamine and Spravato, and saying when established bipolar treatment should stay the priority. A provider who presents ketamine as a bipolar breakthrough is ahead of the evidence.

You can search ketamine clinics near you, or browse IV ketamine infusion clinics and Spravato treatment centers.